Clinical study on the treatment of bronchiectasis in remission period by embedding thread combined with Jianpi Qushi Huayu plaster

Objective:To explore the clinical effect of embedding thread combined with Jianpi Qushi Huayu ointment in the treatment of bronchiectasis in remission period,and to observe the effect on the level of inflammatory cytokines.Methods:150 patients with bronchiectasis in remission period were divided into three groups(50 cases in each group),western medicine group(treated with salmeterol fluticasone and low dose erythromycin),combined group(treated with Jianpi Qushi Huayu plaster),observation group(treated with western medicine+Jianpi Qushi Huayu plaster+embedding thread),and the clinical treatment of the three groups were compared.Result:before and after treatment,the improvement of TCM syndrome score,the improvement of pulmonary ventilation index,the improvement of inflammatory cytokines,and the change of adverse reactions.Results:the treatment efficiency of the observation group and the combination group was significantly higher than that of the western medicine group P The peak level of expiratory flow velocity,the maximum expiratory flow,the forced expiratory volume in one second and the ratio of forced expiratory volume in one second to vital capacity in the observation group and the combined group were significantly better than those in the western medicine group and the pre-treatment level(P<0.05),and the improvement in the observation group was better than that in the combined group After treatment,the expression of IL-13,IL-10 and IL-4 in the combined group was significantly better than that in the western medicine group and before treatment(P<0.05),and the improvement in the observation group was better than that in the combined group;there was no significant difference in the incidence of adverse reactions among the three groups(P>0.05).Conclusion:catgut embedding combined with Jianpi Qushi Huayu ointment can significantly alleviate the related clinical symptoms and signs,effectively control the further aggravation of the disease,improve the lung function of patients,regulate the level of inflammatory cytokines to reduce the degree of inflammatory reaction,and do not significantly aggravate the adverse reactions of drugs.

Role of vitamin D in cystic fibrosis and non-cystic fibrosis bronchiectasis

Bronchiectasis is usually classified as cystic fibrosis(CF) related or CF unrelated(non-CF); the latter is not considered an orphan disease any more, even in developed countries. Irrespective of the underlying etiology, bronchiectasis is the result of interaction between host, pathogens, and environment. Vitamin D is known to be involved in a wide spectrum of significant immunomodulatory effects such as down-regulation of pro-inflammatory cytokines and chemokines. Respiratory epithelial cells constitutively express 1α-hydroxylase leading to the local transformation of the inactive 25(OH)-vitamin D to the active 1,25(OH)_2-vitamin D. The latter through its autocrine and paracrine functions up-regulates vitamin D dependent genes with important consequences in the local immunity of lungs. Despite the scarcity of direct evidence on the involvement of vitamin D deficiency states in the development of bronchiectasis in either CF or non-CF patients, it is reasonable to postulate that vitamin D may play some role in the pathogenesis of lung diseases and especially bronchiectasis. The potential contribution of vitamin D deficiency in the process of bronchiectasis is of particular clinical importance, taking into consideration the increasing prevalence of vitamin D deficiency worldwide and the significant morbidity of bronchiectasis. Given the well-established association of vitamin D deficiency with increased inflammation, and the indicative evidence for harmful consequences in lungs, it is intriguing to speculate that the administration of vitamin D supplementation could be a reasonable and cost effective supplementary therapeutic approach for children with non-CF bronchiectasis. Regarding CF patients, maybe in the future as more data become available, we have to re-evaluate our policy on the most appropriate dosage scheme for vitamin D.

The Role of Vitamin D3 Therapy in Pediatric Bronchiectasis Severity (CF versus non-CF Patients)

Objective: To determine and compare the effect of vitamin D3 supplementation on modifying the disease severity in cystic fibrosis (CF) and non-CF bronchiectasis pediatric patients. Methods: A randomized clinical trial evaluating the role of oral vitamin D3 supplementation for six months, was performed in forty patients with CF and non-CF bronchiectasis under the age of 18 years with vitamin D deficiency or insufficiency. The primary outcome was to reach the sufficient Vitamin D level, the secondary outcome was to reevaluate bronchiectasis severity by following up the frequency, severity of pulmonary exacerbations and lung function after vitamin D3 supplementation. Results: Forty patients completed the trial. The percentage of improvement of vitamin D level after vitamin D3 supplementation for six months was significantly higher in CF (88.3%) than non-CF bronchiectasis patients (59.82%) (P = 0.03). Additionally, moderate to severe pulmonary exacerbations significantly decreased by more than 60%, 45% (P = 0.001, 0.005) and frequent exacerbations decreased by 15%, 10% (P = 0.327, 0.490), while the forced expiratory volume in 1 (FEV1) significantly increased by 17% and 15% in non CF bronchiectasis and CF patients respectively (p < 0.001). Conclusions: Vitamin D3 therapy was effective in decreasing the frequency and severity of pulmonary exacerbations and preserving lung function. Thereby, improving the disease severity even more in non-CF bronchiectasis than CF patients.

The Benefits of Pulmonary Rehabilitation Program on Post-Tuberculosis Bronchiectasis

Pulmonary rehabilitation has emerged as a recommended standard of care for patients with chronic lung disease. As in chronic obstructive pulmonary disease (COPD), persons with other forms of chronic respiratory disease commonly experience deconditioning and decreased quality of life. The aim of this prospective study is to determine the effect of a 4-week pulmonary rehabilitation program (PRP) on patients diagnosed with post-pulmonary tuberculosis bronchiectasis in the Philippines. The participants were above 18 years of age, diagnosed to have stable Post-Pulmonary tuberculosis bronchiectasis with chest computerized tomography (CT) scan or chest radiograph showing bronchiectatic changes, consented to attend the PRP sessions and be included in the study. The subjects underwent PRP for 4 weeks with a total of 8 sessions and determination of Forced expiratory volume at 1 second (FEV1), forced vital capacity (FVC), quality of life determination using the Saint George Respiratory Disease Questionnaire (SGRQ), and exercise endurance using the 6-minute walking test (6 MWT), before and after the PRP. A total of fourteen patients, six males and eight females, aged from 28 - 72 years old, completed the 4-week pulmonary rehabilitation program. There were four ex-smokers and ten non-smokers with concomitant asthma and COPD in some patients. There was significant improvement in the 6-minute walk test and quality of life after 4 weeks of rehabilitation program among the subjects with p value for 6 MWT at p = 0.0001 and p = 0.008 for SGRQ. Conclusion: Pulmonary rehabilitation program led to a significant improvement in exercise capacity and health related quality of life among patients with post-pulmonary tuberculosis bronchiectasis.

Impact of Immunoglobulin E and Airway Obstruction on Bronchiectasis

Introduction: Although an increased prevalence of airway obstruction, bronchial hyperreactivity and allergic diseases such as asthma has been associated with bronchiectasis, studies investigating role of atopy in bronchiectasis are few and controversial. We have therefore studied IgE level and reversible airways obstruction in bronchiectasis which have not previously been evaluated in bronchiectasis. Patients and Methods: This study was conducted at Department of Chest Diseases of Al-Azhar University, Assiut, Egypt from January 2012 to December 2013, all consecutive patients with bronchiectasis admitted to the department were enrolled to the study. Serum IgE, pulmonary function tests (PFT) and high resolution computerized tomography (HRCT) were done to all cases. Results: Patients with high IgE (32/50) had longer disease duration and frequent history of allergic diseases. They also had significantly worse FEV1 (49.38 ± 12.65;p = 0.041) and FEV1/FVC (60.89 ± 13.52, p = 0.015) values. Mean HRCT score was significantly higher in patients with high IgE than in patients with normal (18/50) IgE (23.6 ± 10.1 and 7.83 ± 2.43 respectively). IgE showed positive correlation (r = 0.266, p = 0.015) with HRCT scores. Furthermore, the mean increase in FEV1 after inhalation of salbutamol was significantly greater (p = 0.002) in high IgE patients. Conclusions: In conclusion, IgE level is significantly high in bronchiectasis and it may lead to worse pulmonary function and more HRCT extent. Appreciable reversible airways obstruction should be sought in all cases of bronchiectasis and treated appropriately.

Effect of bronchoscopic ambroxol lavage on inflammatory factors in lavage fluid of patients with bronchiectasis complicated by infection

Objective:To study the effect of bronchoscopic ambroxol lavage on inflammatory factors in lavage fluid of patients with bronchiectasis complicated by infection.Methods:100 patients with bronchiectasis complicated by infection who were treated in our hospital between May 2012 and January 2016 were divided into the control group (n=54) who received conventional treatment and the observation group (n=46) who received intravenous anti-infection combined with bronchoscopic ambroxol lavage after the therapies were reviewed. The contents of inflammatory factors, adhesion molecules and acute phase proteins in lavage fluid were compared between the two groups.Results: Before treatment, the differences in contents of inflammatory factors, adhesion molecules and acute phase proteins in lavage fluid were not statistically significant between two groups of patients. After treatment, inflammatory factors IL-4, IL-6, IL-10 and TNF-α contents in lavage fluid of observation group were lower than those of control group;adhesion molecules sICAM-1 and VCAM-1 contents in lavage fluid were lower than those of control group;acute phase proteins CRP, AAG, HPT and CER contents in lavage fluid were lower than those of control group.Conclusion:Bronchoscopic ambroxol lavage can reduce airway inflammation in patients with bronchiectasis complicated by infection.

380 CASES OF BRONCHIECTASIS WITH HEMOPTYSIS TREATED BY POINT-INJECTION

Hemoptysis,especially the massivehemoptysis caused by bronchiectasis is acommon,but emergent and critical diseases inclinic.Injection of Herba Houttuyniae extractinto Kongzui(LU 6)was performed to treathemoptysis according to the theory oftraditional Chinese medicine and the

慢性牙周炎对支气管扩张症患者生活质量及严重程度的影响

目的:探讨慢性牙周炎对支气管扩张症患者生活质量和疾病严重程度的影响。方法:随机选择2021年4月—2023年4月长沙市第四医院收治的支气管扩张症患者80例作为研究对象,按照是否伴中重度慢性牙周炎将患者分为2组,分别为支气管扩张伴牙周炎组(n=45)和支气管扩张不伴牙周炎组(n=35)。采用支气管扩张生活质量问卷(QoL-B)调查患者的生活质量,采用支气管扩张严重程度指数(BSI)评估疾病严重程度,并检测患者血清高敏C反应蛋白(hsCRP)、肿瘤坏死因子α(TNF-ɑ)、白细胞介素6(IL-6)的水平。采用SPSS 20.0软件包对数据进行统计学分析。结果:支气管扩张伴牙周炎组QoL-B评分显著低于支气管扩张不伴牙周炎组,BSI评分显著高于支气管扩张不伴牙周炎组(P<0.05)。支气管扩张伴牙周炎组hs-CRP、TNF-ɑ、IL-6水平显著高于支气管扩张不伴牙周炎组(P<0.05)。结论:支气管扩张患者中伴有慢性牙周炎的患者在生活质量和疾病严重程度方面都表现出明显的不利影响,可能与炎症反应在2种疾病之间的共同机制有关。

急性加重期支气管扩张症患者血清HGF、LXA4水平与病情程度的关系及其对预后的评估价值

目的探究急性加重期支气管扩张症患者血清肝细胞生长因子(HGF)、脂氧素A4(LXA4)水平与病情程度的关系及其对预后的评估价值。方法选取2019年1月至2021年1月该院诊治的138例急性加重期支气管扩张症患者作为急性加重期组。根据支气管扩张症严重程度指数(BSI评分),分为轻度组(40例)、中度组(46例)及重度组(52例)。根据患者预后,分为预后良好组(85例)和预后不良组(53例)。以同期诊治的70例稳定期支气管扩张症患者作为稳定期组。以同期体检的70例健康者为对照组。采用酶联免疫吸附试验检测血清HGF、LXA4水平。采用Logistic回归模型探讨影响急性加重期支气管扩张症患者预后的因素。采用受试者工作特征(ROC)曲线评估血清HGF、LXA4水平对急性加重期支气管扩张症患者预后的预测作用。结果相比于稳定期组和对照组,急性加重期组血清HGF水平较高,LXA4水平较低(均P<0.05)。急性加重期组患者病情程度越重,血清HGF水平越高,LXA4水平越低。相比于预后良好组,预后不良组血红蛋白、清蛋白、血清LXA4水平较低,而急性加重次数、BSI评分重度比例、血清HGF水平较高(均P<0.05)。急性加重次数(OR=1.185,P<0.001),BSI评分(OR=1.280,P<0.001),血清HGF(OR=1.189,P<0.001)是影响患者预后不良的危险因素,血清LXA4(OR=0.827,P<0.001)是保护因素。血清HGF、LXA4联合检测对患者预后不良评估的曲线下面积为0.912(95%CI:0.862~0.955),大于二者单项检测(Z=4.254、3.819,均P<0.001)。结论急性加重期支气管扩张症患者血清HGF水平升高,LXA4水平降低,二者与病情程度有关,联合检测对患者预后不良具有较高的预测价值。

宣肺降浊清肠汤治疗稳定期支气管扩张症疗效及对肠道微生态的影响

目的观察宣肺降浊清肠汤治疗稳定期支气管扩张患者的效果及对肠道微生态的影响。方法选取2022年1月—2023年1月广州医科大学附属第一医院收治的稳定期支气管扩张症痰湿蕴肺型患者90例为观察对象,随机分为西药组、中药组、中西医结合组,每组各30例;同时于广州医科大学附属第一医院体检中心随机选取30例健康者作为空白组,用于肠道菌群检测的对照。西药组给予氨溴索口服,中药组给予宣肺降浊清肠汤颗粒剂口服,中西医结合组给予宣肺降浊清肠汤联合氨溴索口服。连续治疗6个月后评估3组临床疗效,比较3组治疗前后肺功能指标[第一秒用力呼气容积(FEV_(1))、用力肺活量(FVC)、呼气峰值流速(PEF)]、支气管扩张严重程度指数(BSI)评分、24 h痰量、急性加重次数、咳嗽-咳痰评估问卷(CASA-Q)评分、圣乔治呼吸问卷(SGRQ)评分及粪便标本中直肠真杆菌、多形拟杆菌表达量(采用PCR扩增法测定)。结果治疗结束后,中西医结合组临床总有效率明显高于中药组、西药组[93.3%(28/30)比63.3%(18/30)、76.7%(23/30),P均<0.05]。与治疗前比较,治疗后3组FEV_(1)、FVC、PEF均明显提高,BSI评分、SGRQ评分均明显降低,24 h痰量、急性加重次数均明显减少,CASA-Q评分均明显升高,且中西医结合组各指标改善情况均明显优于中药组及西药组,西药组各指标改善情况均明显优于中药组,差异均有统计学意义(P均<0.05)。治疗后中西医结合组和中药组粪便中直肠真杆菌、多形拟杆菌表达量均较治疗前明显改善(P均<0.05),西药组粪便直肠真杆菌、多形拟杆菌表达量均无明显变化(P均>0.05);治疗后中药组和中西医结合组直肠真杆菌表达量均明显低于西药组(P均<0.05),多形拟杆菌表达量均明显高于西药组(P均<0.05),中药组和中西医结合组直肠真杆菌、多形拟杆菌表达量比较差异均无统计学意义(P均>0.05)。结论宣肺降浊清肠汤联合氨溴索治疗稳定期支气管扩张症痰湿蕴肺型患者效果优于二者单独应用,可有效缓解患者病情,改善肺功能和生活质量,机制可能与宣肺降浊清肠汤可调节肠道菌群微生态相关。

清热化痰汤加减联合纤维支气管镜下肺泡灌洗对支气管扩张患者的影响

目的:探讨清热化痰汤加减联合纤维支气管镜下肺泡灌洗对支气管扩张患者的影响。方法:选取2020年10月—2023年10月浠水县中医院收治的80例支气管扩张患者。根据随机数表法将其分为研究组与常规组,各40例。常规组接受常规西医治疗,研究组在常规组基础上给予清热化痰汤加减联合纤维支气管镜下肺泡灌洗。比较两组治疗后临床疗效,治疗前后临床症状评分、肺功能、血常规指标。结果:研究组总有效率(95.00%)显著高于常规组(77.50%),差异有统计学意义(P<0.05)。治疗后,两组临床症状评分均降低,研究组咳嗽、咳痰、咯血、发热、胸痛、呼吸困难评分均低于常规组,差异有统计学意义(P<0.05)。治疗后,两组肺功能指标均升高,研究组用力肺活量(FVC)和第1秒用力呼气容积(FEV_(1)),最大呼气流速(PEF)均高于常规组,差异有统计学意义(P<0.05)。治疗后,两组血常规指标均降低,研究组白细胞(WBC)计数、中性粒细胞(NEU)计数、淋巴细胞(LYM)计数均低于对照组,差异有统计学意义(P<0.05)。结论:清热化痰汤加减联合纤维支气管镜下肺泡灌洗对支气管扩张患者的治疗有积极的作用,能够明显改善患者肺功能、血常规指标。

支气管扩张合并真菌感染的危险因素分析及列线图模型构建

目的:分析支气管扩张合并真菌感染的危险因素,并构建列线图预测模型。方法:回顾性分析2021年1月—2022年12月钦州市第二人民医院收治的224例支气管扩张患者临床资料,统计合并真菌感染情况,分析患者合并真菌感染的危险因素,并建立列线图模型,划分数据集并评估模型预测性能。结果:224例患者中合并真菌感染80例(35.71%)。多因素Logistic回归分析结果显示,支气管扩张合并真菌感染的独立危险因素包括年龄≥60岁、合并糖尿病、低蛋白血症、合并肺部基础疾病、抗菌药物使用时间≥2周、长期使用糖皮质激素(P<0.05)。训练集与测试集曲线下面积分别为0.720(95%CI:0.636~0.805)、0.828(95%CI:0.726~0.931),准确度分别为0.738、0.742。两集的校准曲线平均绝对误差分别为0.036、0.033。Hosmer-Lemeshow检验显示模型无过度拟合情况(χ^(2)=11.100,P=0.196)。结论:基于支气管扩张合并真菌感染的危险因素建立列线图预测模型,有着较好的预测价值。

双长效支气管扩张剂治疗支气管扩张症合并慢性阻塞性肺疾病的临床效果及肺功能改善效果研究

目的分析双长效支气管扩张剂治疗支气管扩张症合并慢性阻塞性肺疾病(COPD)的临床效果及肺功能改善效果。方法通过盲法、便利抽样、对照原则回顾性研究河北省胸科医院呼吸三科2019年9月至2021年9月接诊的100例支气管扩张症合并COPD患者,根据治疗方法的不同分为观察组和对照组,每组50例。对照组给予噻托溴铵吸入粉雾剂治疗,观察组给予噻托溴铵奥达特罗吸入喷雾剂治疗,治疗6个月。比较2组临床疗效、肺功能、圣乔治呼吸问卷(SGRQ)评分、改良呼吸困难指数(mMRC)评分、动脉血气指标、不良反应总发生率和1年再入院率。结果观察组总有效率高于对照组[96.0%(48/50)比78.0%(39/50)](P=0.007)。观察组治疗2、4、6个月后用力肺活量(FVC)、第1秒用力呼气容积(FEV_(1))、FEV_(1)/FVC均高于对照组,SGRQ评分、mMRC评分均低于对照组,动脉血二氧化碳分压低于对照组,动脉血氧分压高于对照组(均P<0.05)。2组不良反应总发生率比较差异无统计学意义(P=1.000)。观察组1年再入院率低于对照组[2.0%(1/50)比16.0%(8/50)](P=0.036)。结论双长效支气管扩张剂噻托溴铵奥达特罗吸入喷雾剂在改善支气管扩张症合并COPD患者肺功能以及动脉血氧状态方面效果显著,可有效缓解患者呼吸困难等症状,降低再入院率,且安全性较好。

支气管扩张症合并铜绿假单胞菌感染:2012-2022年的文献计量学分析及可视化研究

目的探讨支气管扩张症(支扩症)合并铜绿假单胞菌(PA)感染领域过去十年的研究现状及发展趋势,为该领域的科学研究提供新的思路和策略。方法以“bronchiectasis”or“cystic fibrosis”or“non-cystic fibrosis bronchiectasis”and“Pseudomonas aeruginosa”检索2012—2022年Web of Science Core Collection(WoSCC)发表类型为论著和综述的英文文献,利用HisCite、VOSviewer和Citespace软件对文献发文量、期刊、作者和关键词等进行文献计量学及可视化分析。结果全球共5824篇支扩症合并PA感染的文章发表在1103种期刊上,年均发文量较稳定,以呼吸系统和微生物学期刊为主。共96个国家和地区、5005个机构、21769名作者在该领域发表文章,美国发表文章最多并构建了全球最大合作网络。该领域研究主要集中在肺囊性纤维化,聚类主题包括PA在宿主的适应和进化、炎症反应、抗生素耐药、临床结局和预后。慢性气道感染及各类临床评分标准是近年较为突出的主题。结论支扩症合并PA感染是呼吸系统和微生物学的关注重点,研究主要集中在细菌-宿主相互作用和临床影响,建议中国学者未来更多参与这一领域的基础和临床研究。

中性粒细胞弹性蛋白酶在支气管扩张中的生物学功能及中药干预研究进展

中性粒细胞弹性蛋白酶(NE)是中性粒细胞原代颗粒中的一种主要蛋白酶,参与支气管扩张复杂病理的发生、发展,具有调节炎症反应、控制感染、增加黏液分泌、降解细胞外基质和细胞因子及损害免疫系统等多种生物学功能,与疾病预后有关,可作为临床治疗结果的预测因子和可能的治疗靶点。尚未有大量高级别临床研究证明内源性及外源性NE抑制剂对支气管扩张的疗效。中医药发挥其多靶点、多途径、精准施治等作用干预NE介导的支气管扩张,在改善临床症状、减少急性加重次数、减轻气道炎症反应等方面具有优势。该文综述NE在支气管扩张中的主要生物学功能,以及中医药干预NE介导的气道炎症的进展,期望为临床和科研提供有价值的参考依据。

胸腔镜精准解剖性肺段切除术治疗支气管扩张保留单肺段避免左全肺切除1例

支气管扩张症是一种慢性呼吸系统疾病,其特征是支气管异常且不可逆的扩张、支气管壁破坏和细菌频繁定值[1-2]。临床上,该病主要表现为慢性咳嗽和咳大量脓痰[3],严重支气管扩张患者可能出现危及生命的咯血,并可出现慢性阻塞性气道疾病的特征,如喘息、慢性呼吸衰竭、肺动脉高压和右心衰竭。影像学上根据支气管扩张的形态将支气管扩张症分为柱状、囊状和混合型3型,以双肺下叶、左肺舌段及右肺中叶多见。

支气管扩张症患者气道廓清技术的最佳证据总结

目的检索、评价并整合支气管扩张症患者气道廓清技术(ACT)的最佳证据。方法采用PIPOST模式构建循证问题,按照“6S”金字塔证据模型,系统检索国内外数据库及专业协会网站中关于支气管扩张症患者ACT的指南、临床实践、专家共识、证据总结和系统评价,检索时限为建库至2023年5月1日。结果共纳入14篇文献,包括指南5篇、临床实践2篇、专家共识2篇和系统评价5篇。从评估、干预措施、时间和频率、注意事项、自我管理5个方面,共总结出21条最佳证据。结论医护人员可基于我国国情,考虑患者现状、结合实际临床情境及支气管扩张症患者ACT的最佳证据,制定支气管扩张症患者ACT方案,改善其临床结局,提高生活质量。

加味苇茎汤治疗支气管扩张症稳定期(痰热蕴肺证)的系列单病例随机对照研究

目的评价加味苇茎汤治疗支气管扩张症稳定期(痰热蕴肺证)的临床疗效和安全性。方法运用系列单病例随机对照试验(N-of-1试验)的方法,选取诊断为支气管扩张症稳定期,辨证属于痰热蕴肺证的患者,在一个治疗周期内先后接受两种不同的治疗方案,试验期治疗用加味苇茎汤,对照期治疗用西药氨溴索片,期间设置洗脱期,试验期和对照期的用药先后顺序按随机化方式决定,以目测模拟尺测量法(visual analogue scales,VAS法)评价治疗前后的症状改变,记录24 h痰量和自我评估测试(COPD Assessment Test,CAT)评分,并观察研究期间的不良反应。采用SPSS 25.0、GraphPad Prism 8软件进行统计分析和绘图,入组前的组间差异比较采用独立样本t检验分析;试验期和对照期治疗前后的症状得分、24 h痰量和CAT评分对比,以及两组治疗前后的差值对比采用配对t检验,比较临床差异和统计学差异。结果共有9例患者入组,最终纳入分析的治疗轮次为16次。试验期治疗后中医证候总积分,咳嗽、咳痰、痰液颜色、胸闷胸痛、口苦口干、乏力疲倦等症状,24 h痰量和CAT评分较治疗前改善,差异均具有统计学意义(P<0.05)。试验期和对照期中医证候总积分、痰液颜色评分、胸闷胸痛评分和24 h痰量治疗前后差值比较,试验组较对照组改善明显,差异有统计学意义(P<0.05)。观察期间未出现与试验方法或药物有关的不良事件。结论加味苇茎汤能综合改善支气管扩张症稳定期患者的临床症状,总体疗效优于西药氨溴索,且安全性良好。

特发性支气管扩张伴咯血患者的介入治疗疗效及复发危险因素分析

目的评估支气管动脉栓塞术治疗特发性支气管扩张伴咯血的安全性、有效性并探讨复发的危险因素。方法回顾性收集2020年1月至2023年3月金华市中心医院住院接受支气管动脉栓塞术治疗的108例特发性支气管扩张患者的临床资料,根据出院后是否出现二次咯血将其分为复发组和非复发组,并通过多因素Cox回归分析咯血复发的危险因素。结果108例患者均成功实施支气管动脉栓塞术,共发现403支责任血管。105例患者术后24 h止血,临床成功率为97.2%。出院后中位随访时间为13(8.0,24.8)个月,40例患者出院后咯血复发,咯血复发率为37.0%。多因素Cox回归分析显示,非首次咯血是术后复发的独立危险因素(HR=1.964,95%CI:1.018~3.792,P=0.044)。所有患者均未出现脑梗死、截瘫等严重并发症。结论支气管动脉栓塞术对于特发性支气管扩张伴咯血患者是一种安全、高效的治疗手段,非首次咯血是术后复发的独立危险因素。

自血疗法联合点刺放血治疗支气管扩张症痰热壅肺证临床观察

目的探讨自血疗法联合点刺放血治疗对于支气管扩张症痰热壅肺证的疗效。方法选取2022年7月—2023年3月湖南省直中医医院呼吸科收治的60例支气管扩张症痰热壅肺证患者,随机分配法分为对照组和治疗组,各30例。对照组予以临床常规治疗,治疗组在对照组基础上加以俞募配穴的自血疗法联合点刺放血治疗,记录2组治疗前后的中医症状积分、白细胞(WBC)、中性粒细胞(NEU)、C-反应蛋白(CRP)、白介素-6(IL-6)及临床疗效。结果治疗后,治疗组总有效率高于对照组;2组患者的中医症状积分及炎性因子水平均较治疗前下降,且治疗组低于对照组(P<0.05)。结论自血疗法联合点刺放血治疗支气管扩张症痰热壅肺证效果优于单一临床常规治疗,能够有效降低血清炎性因子,减轻气道炎症反应,改善患者临床症状。